Chi­nese cell ther­a­py biotech de­vel­op­ing TIL ther­a­pies rais­es $60M Se­ries B

Grit Biotech­nol­o­gy said Fri­day that it closed a Se­ries B, rais­ing more than $60 mil­lion from sev­er­al Chi­nese in­vestors.

The fi­nanc­ing came from sev­er­al new in­vestors, in­clud­ing Qian­hai Ark, Lian­do Group, Yuan­he Cap­i­tal and HeFangT­ian Ven­ture Part­ner­ship, in ad­di­tion to pre­vi­ous in­vestors: Sher­pa Health­care Part­ners, Decheng Cap­i­tal and Ma­trix Part­ners Chi­na.

Shang­hai-based Grit said the fund­ing would go to­ward de­vel­op­ing its pipeline, in­clud­ing ad­vanc­ing its tu­mor-in­fil­trat­ing lym­pho­cyte (TIL) can­di­dates and sup­port­ing a planned piv­otal Phase II in Chi­na for its lead can­di­date, GT101. That ther­a­py is cur­rent­ly be­ing test­ed in melanoma and cer­vi­cal and lung can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER